BAT Opens Innovation Center at Global R&D Headquarters in Southampton

BAT by 2FIRSTS.ai
Mar.12.2024
BAT Opens Innovation Center at Global R&D Headquarters in Southampton
BAT opens an innovation center at its global R&D headquarters in Southampton, investing £30 million to enhance research capabilities.

According to a statement on the official website of British American Tobacco (BAT), the company has established an innovation center at its global research and development (R&D) headquarters in Southampton. This center will play a key role in the company's ongoing transformation and in pursuing its vision of creating a "better future".

 

A facility costing £30 million has enhanced and deepened the research and development capabilities of British American Tobacco, providing nine specially designed technology spaces to help develop the company's low-risk product portfolio. The Innovation Centre is dedicated to researching modern oral nicotine pouches, vape liquids and flavors, heated products, as well as new products beyond nicotine.

 

This investment will also support work in packaging, engineering, innovation development, and system integration.

 

The British American Tobacco Company's factory in Southampton has been the location of its research and development operations since 1956. It is one of the largest employers in the region, currently employing over 1,000 staff members from various parts of the UK. Its local supply chain includes over 25 suppliers, spread across more than 30 countries and regions.

 

British American Tobacco has more than 1,600 research and development experts in countries such as the UK, US, Brazil, Indonesia, Malaysia, and China. In 2021, the company opened an innovation center in Trieste, Italy, and in 2022, in Shenzhen, China. British American Tobacco invests 3 billion pounds annually in research and development to develop new category products and establish evidence.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
Former Malaysian Health Minister Allegedly Rejected RM50 Million Bribe Over GEG
Former Malaysian Health Minister Allegedly Rejected RM50 Million Bribe Over GEG
A former political aide has alleged that a RM50 million bribe was offered to Malaysia’s then health minister to abandon the tobacco generational end game (GEG) policy. The claim was published in an opinion article and on social media. No report was made to anti-corruption authorities. Despite the alleged rejection, the GEG provision was later removed from the tobacco bill tabled in Parliament in 2023.
Dec.23 by 2FIRSTS.ai
Exclusive: Suspected ‘Backend Update Then Withdrawal’ Suggests Glas May Be Next FDA-Authorized E-Cigarette Brand After Juul
Exclusive: Suspected ‘Backend Update Then Withdrawal’ Suggests Glas May Be Next FDA-Authorized E-Cigarette Brand After Juul
An exclusive 2Firsts investigation found an unpublished FDA update on e-cigarette marketing authorizations that mirrors market speculation, suggesting Glas’s application may have cleared internal review, though no official confirmation has been issued.
Regulations
Dec.21
UK Disposable Vape Ban Fallout: Convenience Vape Units Down 20.8%, Retailers Hit by a “Triple Whammy,” Talysis Says
UK Disposable Vape Ban Fallout: Convenience Vape Units Down 20.8%, Retailers Hit by a “Triple Whammy,” Talysis Says
UK convenience insight agency Talysis says vape unit sales in convenience stores have fallen 20.8% and value sales 12.7% nearly eight months after the disposable vape ban took effect.
Jan.28 by 2FIRSTS.ai
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
California: Stiiizy hit with another lawsuit alleging high-THC vapes marketed to teens
California: Stiiizy hit with another lawsuit alleging high-THC vapes marketed to teens
A new lawsuit in California state court accuses Stiiizy Inc. of steering high-THC vape products toward teens through youth-appealing branding and weak age verification, alleging the plaintiff’s underage use was followed by cannabis-induced psychosis-related symptoms and significant personal harm.
Feb.06 by 2FIRSTS.ai